Meeting Series


Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Clinical Practice Guidelines

A Guide to Comprehensive Hepatitis C Counseling and Testing.

Centers for Disease Control and Prevention (CDC).

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. 

American Association for the Study of Liver Diseases/Infectious Diseases Society of America, 2017. 

Hepatitis C: Screening.

U.S. Preventive Services Task Force, 2013. 

Clinical Resources for HCV Treaters

Drugs, Brains, and Behavior: The Science of Addiction: Treatment and Recovery.

National Institute on Drug Abuse, 2014.

Harm Reduction Coalition. 

The Science of Drug Abuse and Addiction: The Basics.

National Institute on Drug Abuse, 2016.

Today’s Heroin Epidemic.

Centers for Disease Control and Prevention, 2015.

Viral Hepatitis Surveillance — United States, 2015. 

Centers for Disease Control and Prevention, 2015. 

Clinical Resources for Addiction Services Providers

Philadelphia HCV Treatment Provider Directory

Hepatitis C Infection.

American Society of Addiction Medicine, 2017.

A Medical Provider Guide: Screening for Hepatitis C Infection in People Who Inject Drugs.

Project Inform.

Patient Resources

Addiction Group

Addiction Group is an informational website that provides authoritative medical content and treatment resources for individuals with substance use disorders, alcohol use disorders, and/or co-occurring mental health disorders.

Getting Off Right: A Safety Manual for Injection Drug Users.

The Harm Reduction Coalition has produced a compilation of unbiased medical facts, injection techniques, and common sense, with the goal of reducing harm and promoting individual and community health.

Hep C 123: Diagnosis, Treatment & Support.

American Liver Foundation, 2017. The American Liver Foundation’s Hep C 123 website is a dedicated online information and resource center created in support of individuals impacted by HCV infection.

Hepatitis C and Injection Drug Use.

The CDC is a division within the US Department of Health and Human Services (DHHS), the principal agency for protecting the health of all Americans. This webpage provides concise information regarding HCV risk, transmission, and prevention in people who inject drugs.

Hepatitis C FAQs for the Public.

The CDC is a division within the US Department of Health and Human Services (DHHS), the principal agency for protecting the health of all Americans. This patient-directed website addresses basics across the HCV clinical continuum. is a website for people living with HCV that offers education, tools, and resources. Articles are written by people living with or cured of HCV, patient advocates, and medical providers. 

The Body Pro: Spotlight Center on Hepatitis C.

Hepatitis C Prevention for People Who Inject Drugs, 2016. This article provides real-world best practices for preventing HCV infection.

Pill-Reminder Smartphone Apps (Free)

Mango Health — Medicine Manager, Pill Reminder

iPhone  and Android

Medisafe Pill Reminder, RX & Medicine Tracker

iPhone and Android

Suggested Readings

Awareness of HCV infection among persons who inject drugs in San Diego, California.

Collier MG, et al. Am J Public Health. 2015;105(2):302–303.

Doing the math on hepatitis C virus treatment.

Mehta SH, Thomas DL. J Hepatol. 2016;65(1):5-6.

Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.

McLellan AT, et al. JAMA. 2000;284(13):1689-1695.

Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials.

Grebely J, et al. Clin Infect Dis. 2016;63(11):1405-1411.

Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials.

Grebely J, et al. Clin Infect Dis. 2016;63(11):1479-1481.

Elbasvir/grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial.

Dore GJ, et al. Ann Intern Med. 2016;165(9):625-634.

Emerging and underrecognized complications of illicit drug use.

Wurcel AG, et al. Clin Infect Dis. 2015;61(12):1840-1849.

Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals.

Rich ZC, et al. BMC Public Health. 2016;16:994.

Hepatitis C virus serosorting in people who inject drugs: sorting out the details.

Kim AY, Page K. J Infect Dis. 2013;208(12):1929-1931.

Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.

Islam N, et al. Lancet Gastroenterol Hepatol. 2017;2(3):200-210.

Medical and behavioral approaches to engage people who inject drugs into care for hepatitis C virus infection.

Gonzalez SA, et al. Addict Disord Their Treat. 2017;16(2 suppl 1):S1-S23.

National Viral Hepatitis Action Plan 2017–2020.

U.S. Department of Health and Human Services, 2017.

Outcomes from a large 10-year hepatitis C treatment programme in people who inject drugs: no effect of recent or former injecting drug use on treatment adherence or therapeutic response.

Elsherif O, et al. PLoS One. 2017;12(6):e0178398.

SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy.

Grebely J, et al. European Association for the Study of the Liver. The International Liver Congress™ − EASL 2017. April 19-23, 2017; Amsterdam, The Netherlands.

Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study.

Bruneau J, et al. Clin Infect Dis. 2014;58(6):755-761.

The cost-effectiveness of harm reduction.

Wilson DP, et al. Int J Drug Policy. 2015:26(suppl 1):S5-S11.

The HCV care continuum does not end with cure: a call to arms for the prevention of reinfection.

Falade-Nwulia O, Sulkowski M. J Hepatol. 2017;66(2): 267-269.

Treating Medicaid patients with hepatitis C: clinical and economic impact.

Younossi Z, et al. Am J Manag Care. 2017;23(2):107-112.

Treatment of HCV in persons who inject drugs: treatment as prevention.

Grebely J, Dore GL. Clin Liver Dis. 2017;9(4):77-80.


Action and Advocacy



Health literacy and liver disease.

Gulati R, et al. Clin Liver Dis. 2018;11(2):48-51.

Hepatitis Education Project.

The Hepatitis Education Project provides support, education, advocacy, and direct services for people affected by hepatitis, and works to raise hepatitis awareness among patients, medical providers, and the general public.

National Hepatitis Corrections Network.

The National Hepatitis Corrections Network (NHCN) supports a public health approach to hepatitis education, prevention, testing, and treatment in prisons and jails.

Project ECHO (Extension for Community Healthcare Outcomes).

Project ECHO is a collaborative, telecommunications-based model of medical education and care management designed to train primary care clinicians to provide specialty care in rural and underserved areas.

Training Materials and Resources.

Substance Abuse and Mental Health Services Administration (SAMHSA), 2018.




Drug purchasing strategies to treat people with hepatitis C in the criminal justice system.

Akiyama MJ, et al. Am J Public Health. 2018;108(5):607-608.

Health Reform’s Medicaid Expansion.

Center on Budget and Policy Priorities, 2019.

Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) and National Viral Hepatitis Roundtable (NVHR).

Together, CHLPI and NVHR continue to play a pivotal role in removing Medicaid restrictions on HCV treatment. An interactive map allows you to see each state’s Medicaid restrictions. Last updated November 2018.

Economic and public health impacts of policies restricting access to hepatitis C treatment for Medicaid patients.

Chidi AP, et al. Value Health. 2016;19(4):326-334.

Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial.

Kattakuzhy S, et al. Ann Intern Med. 2017;167(5):311-318.

National Viral Hepatitis Roundtable.

The National Viral Hepatitis Roundtable (NVHR) is a coalition working together to eliminate hepatitis B and C in the United States.



National Viral Hepatitis Roundtable: Online Resources.


Coverage/Coding and Billing.

This page supplies information regarding coding and billing for hepatitis services.

Implementing Electronic Medical Record Prompts for Baby Boomer Screening.

This page provides a variety of resources for implementing clinical decision support tools and/or HCV-testing prompts in electronic medical records (EMRs).

Resources for Training Primary Care Providers and Other Health Care Workers About HCV Screening and Linkage to Care.

This page furnishes or links to a variety of resources, including CARE-NAVIGATION TOOLS:

  • HCV Treatment and Insurance Protocol: Prior Authorization Process
  • Medicare Learning Network (MLN) Matters: Submitting Claims to Medicare for HCV Screening
  • Sample Appeals Letters (Templates)




North American Syringe Exchange Network (NASEN).

NASEN provides a directory of syringe exchange programs that can be located by zip code, landmark, city, or state.

SAMHSA: Behavioral Health Treatment Services Locator.

SAMHSA provides confidential and anonymous information on substance abuse and mental health treatment facilities throughout the United States and its territories.

SAMHSA: Medication-Assisted Treatment (MAT) Support Organizations.

SAMHSA provides numerous links to nonprofit associations, federal agencies, and patient groups that offer support for providers of medication-assisted treatment (MAT), as well as patients and families.

Interactive Presentation

Have You Ever Injected Drugs? What You Need to Know About Hepatitis C

Current or past injection drug use puts you at high risk for hepatitis C infection. But there is good news for those who are infected: New treatments are available that cure most people—even injection drug users. This video provides important information on your risk for Hepatitis C, getting tested, and—if you're infected—getting cured.


Building Bridges to Reach People Who Inject Drugs with the Goal to Eliminate HCV

Relevant Resources

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Targeting NASH

Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis

Hepatitis C is Curable

Got it? Treat it!

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist


Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

The Nexus of NASH and Type 2 Diabetes Mellitus

The Emerging Role of the Diabetologist

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

The Changing Landscape of IBD

Emerging Concepts in Patient Management

The Big (& Small) Picture of Nonalcoholic Steatohepatitis

Building Your Understanding to Combat a Growing Problem

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

HIV as a Chronic Disease

A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Trends and Updates in IBD

Appraising the Therapeutic Armamentarium in Moderate and Severe Disease

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP

Evolving Models of HIV Care (Volume 3)

The Rapid ART Standard of Care: From Evidence to Healthcare Equity

HIV Updates for Pharmacy Practice

Maximizing Your Role to Impact Patient Outcomes


Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Case Challenges in HIV Medicine

Benefits, Barriers, & Best Practices in an Advancing Field

Challenges and Opportunities in HIV

Practical Solutions Across the Spectrum of Care

Expanding HIV Prevention in Colorado—and Nationwide

A PEP/PrEP Training Guide for Pharmacists

Setting a Course for the Optimal Management of IBD

An Interactive Learning Experience

Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up to Date?

A Focus on Clinical Evidence and Guideline Recommendations

Treating Hepatitis C in the Primary Care Setting

A Critical Step Toward HCV Elimination

Honing Clinical Skills in HIV Treatment

Considering the Patient, the Provider, and the Science

Hot Topics in HCV

A Multidisciplinary Online Mini-Curriculum

IBD Journal Club:

Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD

Clinical Issues in COVID-19

Debates and Discussions about Monoclonal Antibody Therapies

Minimizing Patient Risks From COVID-19

An Update on Monoclonal Antibody Therapies

Treating Hepatitis C in the Primary Care Setting

Establishing Clinical Readiness Through Mentored Learning

Finding the Path in Eosinophilic Esophagitis

Interdisciplinary Strategies for Adult and Pediatric Patients

Answering the Call

Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema

Putting a Spotlight on Systemic Mastocytosis

A Multidisciplinary Look at Early Diagnosis and Management

Clinical Updates in COVID-19

Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment

Is It Systemic Mastocytosis?

Best Practices for Diagnosis and Management

Monoclonal Antibodies for COVID-19

An Update on Best Practices

Monoclonal Antibodies for COVID-19

New Avenues to Pre-Exposure Prophylaxis

Virologic Failure in HIV

An Updated Clinician’s Guide to Assessment and Management

Applying HIV Advances in Practice

What the Pharmacist Needs to Know

Buffing Up on New and Emerging ART

A Look at the Changing HIV Playing Field

Pharmacy PrEP Education

A “How To” Series Spanning Policy to Practice


Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention

Long-Acting Injectable PrEP:

Bringing HIV Prevention to a New Level

PrEParing to End the Epidemic

Optimizing HIV Prevention in Primary Care